In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Precision BioSciences Inc.

www.precisionbiosciences.com

Latest From Precision BioSciences Inc.

Venture Funding Deals: Recent Rounds For Gene-Editing Plays Top $300m

Gene-editing focused start-ups Beam Therapeutics, Gracell, Snipr Biome and Precision Biosciences raised a total of $310m in financings in February and March. For other recent venture funding deals... 
Deals Financing

Finance Watch: Genfit Launches IPO To Expand US Presence Ahead Of Phase III NASH Results

Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.

Financing Business Strategies

Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies

Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.

Financing StartUps and SMEs

Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish

Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Precision BioSciences Inc.
  • Senior Management
  • Matthew Kane, CEO
    Abid Ansari, CFO
    Derek Jantz, PhD, CSO
    David Thomson, PhD, Chief Dev. Officer
    Jeff Smith, PhD, CTO
    Christopher H Heery, MD, CMO
    David Thomson, PhD, COO
  • Contact Info
  • Precision BioSciences Inc.
    Phone: (919) 314-5512
    302 East Pettigrew St., Dibrell Bldg.
    Ste. A-100
    Durham, NC 27701
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register